Takeda Pharmaceutical Co. Ltd. licensed some cancer assets to Chordia Therapeutics, a spinoff started by six former Takeda scientists with funding from the company and a venture capital syndicate, FierceBiotech reported.
The cancer assets, including preclinical CDC-like kinase inhibitors and an adult T cell leukemia lymphoma drug, had been pushed lower in Takeda's drug development pipeline. They were picked up by Chordia as the company started rethinking its research and development strategy.
The team of six oncology research scientists also received laboratory space at the company's Shonan site in Japan, Takeda reported in its second-quarter results.
Takeda alongside the venture capital syndicate of Kyoto University Innovation Capital, Mitsubishi UFJ Capital and SMBC Venture Capital participated in Chordia's series A funding, FierceBiotech said.
